Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 4
1975 8
1976 5
1977 4
1978 9
1979 5
1980 6
1981 4
1982 2
1983 8
1984 11
1985 9
1986 6
1987 9
1988 11
1989 9
1990 19
1991 17
1992 15
1993 19
1994 25
1995 20
1996 13
1997 15
1998 46
1999 28
2000 26
2001 30
2002 68
2003 97
2004 151
2005 159
2006 143
2007 122
2008 173
2009 145
2010 177
2011 159
2012 150
2013 132
2014 151
2015 154
2016 172
2017 177
2018 140
2019 188
2020 200
2021 159
2022 89
2023 52
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

3,204 results

Results by year

Filters applied: . Clear all
Page 1
Azetidines of pharmacological interest.
Parmar DR, Soni JY, Guduru R, Rayani RH, Kusurkar RV, Vala AG. Parmar DR, et al. Arch Pharm (Weinheim). 2021 Nov;354(11):e2100062. doi: 10.1002/ardp.202100062. Epub 2021 Jun 29. Arch Pharm (Weinheim). 2021. PMID: 34184778 Review.
Azelnidipine.
Wellington K, Scott LJ. Wellington K, et al. Drugs. 2003;63(23):2613-21; discussion 2623-4. doi: 10.2165/00003495-200363230-00004. Drugs. 2003. PMID: 14636080 Review.
Ezetimibe and Insulin Resistance.
Popovic DS, Papachristou S, Stokic E, Papanas N. Popovic DS, et al. Curr Vasc Pharmacol. 2022;20(4):315-317. doi: 10.2174/1570161120666220301140528. Curr Vasc Pharmacol. 2022. PMID: 35232351 No abstract available.
Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials.
Bieber T, Katoh N, Simpson EL, de Bruin-Weller M, Thaçi D, Torrelo A, Sontag A, Grond S, Issa M, Lu X, Cardillo T, Holzwarth K, Thyssen JP. Bieber T, et al. J Dermatolog Treat. 2023 Dec;34(1):2161812. doi: 10.1080/09546634.2022.2161812. J Dermatolog Treat. 2023. PMID: 36546346 Free article.
Ezetimibe.
Harris M, Davis W, Brown WV. Harris M, et al. Drugs Today (Barc). 2003 Apr;39(4):229-47. doi: 10.1358/dot.2003.39.4.799401. Drugs Today (Barc). 2003. PMID: 12743640 Review.
Utility of ezetimibe.
Ashikaga H, Blumenthal RS, Jones SR. Ashikaga H, et al. Am J Cardiol. 2009 May 1;103(9):1321-2. doi: 10.1016/j.amjcard.2009.01.019. Epub 2009 Mar 5. Am J Cardiol. 2009. PMID: 19406279 No abstract available.
Baricitinib-induced paradoxical psoriasis.
Di Domizio J, Castagna J, Algros MP, Prati C, Conrad C, Gilliet M, Wendling D, Aubin F. Di Domizio J, et al. J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e391-e393. doi: 10.1111/jdv.16293. Epub 2020 Mar 6. J Eur Acad Dermatol Venereol. 2020. PMID: 32052886 No abstract available.
Baricitinib: First Global Approval.
Markham A. Markham A. Drugs. 2017 Apr;77(6):697-704. doi: 10.1007/s40265-017-0723-3. Drugs. 2017. PMID: 28290136 Review.
3,204 results